Notification
No new Notification messages
Zinka Logistics Solutions IPO is Open!
Apply for the Zinka Logistics Solutions IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
concord drugs limited stock

Concord Drugs Limited Share Price

35.33 -1.16 (-3.17%)
Nov 21 2024 03:28 PM Pharmaceuticals NSE: CONCORD

Concord Drugs Limited Share Price Update

As of the latest trading session, Concord Drugs Limited share price is currently at 35.33, which is down by -1.16 from its previous closing. Today, the stock has fluctuated between 35.02 and 38.95. Over the past year, Concord Drugs Limited has achieved a return of 7.95 %. In the last month alone, the return has been -1.37 %. Read More...

Concord Drugs Limited Performance

Day Range

Low35.02 High38.95
35.74

52 Week Range

Low 30.59 High 61.50
35.74

Concord Drugs Limited Share Price

538965

CONCORD

img img img img
No Data Available

Open Price

38.95

Prev. Close

36.49

Volume (Shares)

3314.00

Total traded value

1.18

Upper Circuit

43.78

Lower Circuit

29.20

Note: The current prices & values are delayed, Login to your account for live updates.

Concord Drugs Limited Fundamentals


(Standalone)

Market Cap (Cr) 35.33
PE Ratio (TTM) -67.43
Book Value / Share 33.88
Beta 0.77
ROE 1.28%
EPS (TTM) 0.00
Dividend Yield 0.00%
Net Profit Qtr (Cr) 0.05

Concord Drugs Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 11.84
Operating Expense 11.78
Net Profit 0.05
Net Profit Margin (%) 0.42
Earnings Per Share (EPS) 0.05
EBITDA 0.80
Effective Tax Rate (%) 28.57
Particulars JUN 2024 (Values in Cr)
Revenue 6.35
Operating Expense 6.33
Net Profit 0.01
Net Profit Margin (%) 0.15
Earnings Per Share (EPS) 0.01
EBITDA 0.74
Effective Tax Rate (%) 33.33
Particulars MAR 2024 (Values in Cr)
Revenue 14.47
Operating Expense 15.05
Net Profit -0.35
Net Profit Margin (%) -2.41
Earnings Per Share (EPS) -0.35
EBITDA 0.19
Effective Tax Rate (%) 37.93
Particulars DEC 2023 (Values in Cr)
Revenue 12.62
Operating Expense 12.87
Net Profit -0.24
Net Profit Margin (%) -1.90
Earnings Per Share (EPS) -0.24
EBITDA 0.55
Effective Tax Rate (%) 7.69
Particulars SEP 2023 (Values in Cr)
Revenue 7.38
Operating Expense 6.63
Net Profit 0.53
Net Profit Margin (%) 7.18
Earnings Per Share (EPS) 0.56
EBITDA 1.52
Effective Tax Rate (%) 31.57
Particulars MAR 2024 (Values in Cr)
Revenue 43.26
Operating Expense 42.71
Net Profit 0.42
Net Profit Margin (%) 0.97
Earnings Per Share (EPS) 0.42
EBITDA 3.69
Effective Tax Rate (%) 25.00
Particulars MAR 2023 (Values in Cr)
Revenue 51.31
Operating Expense 50.19
Net Profit 0.89
Net Profit Margin (%) 1.73
Earnings Per Share (EPS) 0.96
EBITDA 4.35
Effective Tax Rate (%) 20.35
Particulars MAR 2022 (Values in Cr)
Revenue 58.96
Operating Expense 56.81
Net Profit 1.59
Net Profit Margin (%) 2.69
Earnings Per Share (EPS) 1.82
EBITDA 5.68
Effective Tax Rate (%) 28.88
Particulars MAR 2021 (Values in Cr)
Revenue 51.36
Operating Expense 50.92
Net Profit 3.28
Net Profit Margin (%) 6.38
Earnings Per Share (EPS) 3.75
EBITDA 7.08
Effective Tax Rate (%) 23.54
Particulars MAR 2020 (Values in Cr)
Revenue 51.34
Operating Expense 51.00
Net Profit 0.33
Net Profit Margin (%) 0.64
Earnings Per Share (EPS) 0.38
EBITDA 3.46
Effective Tax Rate (%) 28.26
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.43
ROCE % 4.76
Total Debt to Total Equity 0.53
EBITDA Margin 9.02
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 3.30
ROCE % 6.04
Total Debt to Total Equity 0.56
EBITDA Margin 8.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.61
ROCE % 8.36
Total Debt to Total Equity 0.58
EBITDA Margin 9.65
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.82
ROE % 1.28
ROCE % 4.25
Total Debt to Total Equity 0.47
EBITDA Margin 8.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 33.43
ROE % 2.96
ROCE % 5.67
Total Debt to Total Equity 0.53
EBITDA Margin 8.48
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.44
ROE % 5.77
ROCE % 8.80
Total Debt to Total Equity 0.53
EBITDA Margin 9.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.61
ROE % 1.59
ROCE % 5.01
Total Debt to Total Equity 0.45
EBITDA Margin 6.46
Particulars MAR 2020 (Values in Cr)
Book Value / Share 26.86
ROE % 1.42
ROCE % 5.61
Total Debt to Total Equity 0.42
EBITDA Margin 6.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.17
Total Assets 58.80
Total Liabilities 58.80
Total Equity 33.81
Share Outstanding 10000000
Price to Book Ratio 1.04
Return on Assets (%) 0.80
Return on Capital (%) 0.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 58.23
Total Liabilities 58.23
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.69
Return on Capital (%) 2.06
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 56.29
Total Liabilities 56.29
Total Equity 33.81
Share Outstanding 10000000
Price to Book Ratio 1.04
Return on Assets (%) 0.74
Return on Capital (%) 0.88
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 56.63
Total Liabilities 56.63
Total Equity 31.70
Share Outstanding 9315470
Price to Book Ratio 0.82
Return on Assets (%) 1.57
Return on Capital (%) 1.92
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 56.44
Total Liabilities 56.44
Total Equity 28.36
Share Outstanding 8743750
Price to Book Ratio 0.89
Return on Assets (%) 2.82
Return on Capital (%) 3.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 49.88
Total Liabilities 49.88
Total Equity 26.76
Share Outstanding 8743750
Price to Book Ratio 0.95
Return on Assets (%) 6.57
Return on Capital (%) 8.26
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 58.01
Total Liabilities 58.01
Total Equity 23.48
Share Outstanding 8743750
Price to Book Ratio 0.49
Return on Assets (%) 0.56
Return on Capital (%) 0.99
Particulars MAR 2024 (Values in Cr)
Net Income 0.62
Cash from Operations 1.01
Cash from Investing -1.00
Cash from Financing 0.28
Net change in Cash 0.06
Free Cash Flow 2.03
Particulars MAR 2023 (Values in Cr)
Net Income 1.24
Cash from Operations 2.04
Cash from Investing -2.26
Cash from Financing 0.62
Net change in Cash 0.02
Free Cash Flow 2.89
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2024 (Values in Cr)
Net Income 0.55
Cash from Operations 2.16
Cash from Investing -1.20
Cash from Financing -0.68
Net change in Cash 0.06
Free Cash Flow 3.18
Particulars MAR 2023 (Values in Cr)
Net Income 1.12
Cash from Operations 2.59
Cash from Investing -2.26
Cash from Financing 0.05
Net change in Cash 0.03
Free Cash Flow 3.44
Particulars MAR 2022 (Values in Cr)
Net Income 2.24
Cash from Operations 1.44
Cash from Investing -2.44
Cash from Financing 1.67
Net change in Cash 0.00
Free Cash Flow 3.90
Particulars MAR 2021 (Values in Cr)
Net Income 4.29
Cash from Operations 2.08
Cash from Investing -3.66
Cash from Financing 2.07
Net change in Cash 0.02
Free Cash Flow 5.76
Particulars MAR 2020 (Values in Cr)
Net Income 0.45
Cash from Operations 2.60
Cash from Investing -0.84
Cash from Financing -1.79
Net change in Cash -0.14
Free Cash Flow 3.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.85 48.57 9.49 428.00 37.54 / 77.70
AMRUTAJAN HEALTH LTD 720.90 43.85 6.99 2084.17 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6497.50 126.19 23.91 16243.75 4050.15 / 8139.85
BLISS GVS PHARMA LTD 120.75 15.72 1.24 1271.52 92.25 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 36.30
  • 26 Days 36.80
  • 10 Days 36.70
  • 50 Days 37.00
  • 12 Days 36.80
  • 100 Days 37.50
  • 20 Days 36.80
  • 200 Days 42.10
36.30
PIVOT
First Resistance 37.19
Second Resistance 37.89
Third Resistance 38.78
First Support 35.60
Second Support 34.71
Third Support 34.01
RSI 51.66
MACD -0.02
Commodity Channel Index (CCI) -33.65
ADX 8.91
Williams % R -70.09

Over 1 Month

down

-1.37

Over 3 Months

down

12.07

Over 6 Months

down

-7.26

Over 1 Year

down

7.95

Over 3 Years

down

7.83

Over 5 Years

down

14.18

Concord Drugs Limited Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

Concord Drugs Limited Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
45.6
Promoter Holdings
54.39
FII
0.0
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Nagi Reddy Seelam Shareholding of Promoter and Promoter Group 2860536.0 28.61
S. Manoj Kumar Reddy Shareholding of Promoter and Promoter Group 1628125.0 16.28
Seelam Koni Reddy Shareholding of Promoter and Promoter Group 950543.0 9.51
Rajender Kumar Agarwal Public Shareholding 168633.0 1.69
Sushil Kumar Agarwal Public Shareholding 130400.0 1.3
Manju Agarwal Public Shareholding 130140.0 1.3
S N Thulasi Devi Public Shareholding 121200.0 1.21
K Ramesh Reddy Public Shareholding 104600.0 1.05
Mohan Thodupunuri Public Shareholding 100006.0 1.0
Ekta Vijaywargi Public Shareholding 100000.0 1.0
Rakesh K Public Shareholding 100000.0 1.0
Sannuthi Lokesh Public Shareholding 100000.0 1.0

Concord Drugs Limited

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About Concord Drugs Limited

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by Concord Drugs Limited

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Concord Drugs Ltd?

Answer Field

The share price of Concord Drugs Ltd for NSE is ₹ 0.00 and for BSE is ₹ 35.74.

What is the Market Cap of Concord Drugs Ltd?

Answer Field

The market cap of Concord Drugs Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 35.70 Cr. as of now.

What is the 52 Week High and Low of Concord Drugs Ltd?

Answer Field

The 52 Week High and Low of Concord Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 61.50 and ₹ 30.59.

How to Buy Concord Drugs Ltd share?

Answer Field

You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Concord Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 7.95%.

What is the Current Share Price of Concord Drugs Ltd?

Answer Field

Concord Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 35.74 as on Nov 21 2024 03:28 PM.

What is the Market Cap of Concord Drugs Ltd Share?

Answer Field

The market cap of Concord Drugs Ltd for NSE ₹ 0.0 & for BSE ₹ 35.70 as on Nov 21 2024 03:28 PM.

What is the P/E Ratio of Concord Drugs Ltd Share?

Answer Field

As on Nov 21 2024 03:28 PM the price-to-earnings (PE) ratio for Concord Drugs Ltd share is -67.43.

What is the PB ratio of Concord Drugs Ltd Share?

Answer Field

As on Nov 21 2024 03:28 PM, the price-to-book (PB) ratio for Concord Drugs Ltd share is 33.88.

How to Buy Concord Drugs Ltd Share?

Answer Field

You can trade in Concord Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Concord Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Concord Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Concord Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader